Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Samsung Electronics (005930) – Investor Relations (IR) Holding Announcement / 2024-01-09

Posted on January 9, 2024July 29, 2026 By K-STOCK Editor No Comments on [Disclosure] Samsung Electronics (005930) – Investor Relations (IR) Holding Announcement / 2024-01-09

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Samsung Electronics will hold an earnings conference call on January 31, 2024, at 10:00 AM KST for investors and media to present its Q4 2023 financial results.

📊 [Summary of Key Disclosure Details & Figures]

  • Event Name: Q4 2023 Earnings Release Investor Relations (IR)
  • Date & Time: January 31, 2024, 10:00 AM KST
  • Target Audience: Investors, Analysts, Media, etc.
  • Purpose: Presentation of Q4 2023 business performance
  • Format: Conference Call (Simultaneous Korean/English translation and webcasting provided)
  • Key Content: Q4 2023 financial results and Q&A session
  • IR Material Release Date: January 31, 2024
  • Board/Decision Date: January 09, 2024
  • Other Important Details:
    • Live webcasting available via the Samsung Electronics IR website
    • Questions from investors collected starting January 9 to address key shareholder topics during the conference call

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Review of IR Presentation Release and Q&A Results

Verifying the financial performance figures and responses to pre-submitted shareholder questions presented at this IR event is important to understand the Q4 business results and Q&A details. Related information can be verified in the official IR materials published on the event date and upcoming periodic reports (Annual, Quarterly, or Half-Year Reports).

📢 Disclaimer & Source Notice

Source: This content was structured and regenerated based on official filings submitted to the Financial Supervisory Service’s DART system.

Investment Risk Warning: This content is provided strictly for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific security. All investment decisions and financial liabilities rest entirely with the individual investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] SK hynix(000660) – Investor Relations (IR) Presentation / 2024-01-09
Next Post: [Disclosure] Samsung Electronics (005930) – Provisional Consolidated Financial Performance (Fair Disclosure) / 2024-01-09

Related Posts

[Disclosure] SK Hynix (000660) – Future Business and Management Plan (Fair Disclosure) / 2026-04-22 Disclosures
[Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2025-08-27 Disclosures
[Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P44 (Darzalex Biosimilar) in South Korea / 2025-03-20 Disclosures
[Disclosure] Samsung Electro-Mechanics (009150) – Consolidated Earnings Announcement (Provisional) / 2025-10-29 Semiconductors
[Disclosure] Jeju Semiconductor (080220) – Decision on Disposal of Treasury Stocks / 2024-02-21 Semiconductors
[Disclosure] Hyundai Motor (005380) – Notice of Interim (Quarterly) Ex-Dividend Reference Price for Common Stock (KRW 681,000) Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme